Flagship 3 aims to develop sensor systems to detect and identify bacterial pathogens, including Clostridium difficile, MRSA and VRE (Vancomycin Resistant Enterococci).
Mobile diagnostics will be developed for use in GP surgeries and care homes, taking advantage of new biomarker discovery tools to guide the development of a variety of capture molecules.
A range of sensor platform technologies will be developed including lateral flow tests with novel enzyme-nanoparticle tags, where results are read using low power impedance CMOS microchips.
Mobile diagnostics will be linked to a health dashboard, with the potential to also link self-reported symptoms from the web.
